Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating Serum Lipid Metabolites for Potential Biomarkers for Psoriatic Arthritis Musculoskeletal Disease Activity and Severity
FY 2022-23
Summary
Psoriatic Arthritis (PsA) is a long-term disease characterized by scaly skin wounds, joint pain and swelling. PsA can lead to joint destruction and disability if treated too late. But PsA is often mistaken for other similar diseases and require multiple laboratory and doctor visits to confirm. Currently, one of the best methods to detect this disease is using ultrasound to image the joints for signs of PsA. But this method is time-consuming and impractical for doctors to use on a regular basis. PsA is known to affect approximately 0.75% of Canadians today and is estimated to increase in the future. Thus, it is important to create a diagnostic method that will quickly, easily, and confidently determine whether you have PsA and how bad it is. Metabolomics is a new research field that studies the metabolites involved in your body processes. These metabolites are small molecules or compounds that can tell us what has happened and what is happening in your body, a snapshot of how your body is functioning. We know that people with PsA have different levels of metabolites compared to healthy people, but it is unknown if metabolite levels vary by disease severity. Thus, we believe that if we measure metabolites belonging to PsA, we can create a better diagnostic method based around measuring a set of metabolites that differs by severity of PsA. To do this research, we will collect blood from PsA patients diagnosed via ultrasound. We will use a novel technique, Solid-Phase Microextraction to gather metabolites from the blood. Liquid Chromatography will separate the metabolites to make it easier for the Mass Spectrometer to identify the metabolites and their amount. Finally, we can use statistical analysis to identify a set of metabolites that are signs of PsA and its severity.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486016
Name
Li Sheng Han
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Serum Lipid Metabolites for Potential Biomarkers for Psoriatic Arthritis Musculoskeletal Disease Activity and Severity
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Lipidomics; Liquid Chromatography-Mass Spectrometry; Metabolomics; Musculoskeletal; Psoriatic Arthritis; Solid-Phase Microextraction
Abstract
Psoriatic Arthritis (PsA) is a long-term disease characterized by scaly skin wounds, joint pain and swelling. PsA can lead to joint destruction and disability if treated too late. But PsA is often mistaken for other similar diseases and require multiple laboratory and doctor visits to confirm. Currently, one of the best methods to detect this disease is using ultrasound to image the joints for signs of PsA. But this method is time-consuming and impractical for doctors to use on a regular basis. PsA is known to affect approximately 0.75% of Canadians today and is estimated to increase in the future. Thus, it is important to create a diagnostic method that will quickly, easily, and confidently determine whether you have PsA and how bad it is. Metabolomics is a new research field that studies the metabolites involved in your body processes. These metabolites are small molecules or compounds that can tell us what has happened and what is happening in your body, a snapshot of how your body is functioning. We know that people with PsA have different levels of metabolites compared to healthy people, but it is unknown if metabolite levels vary by disease severity. Thus, we believe that if we measure metabolites belonging to PsA, we can create a better diagnostic method based around measuring a set of metabolites that differs by severity of PsA. To do this research, we will collect blood from PsA patients diagnosed via ultrasound. We will use a novel technique, Solid-Phase Microextraction to gather metabolites from the blood. Liquid Chromatography will separate the metabolites to make it easier for the Mass Spectrometer to identify the metabolites and their amount. Finally, we can use statistical analysis to identify a set of metabolites that are signs of PsA and its severity.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Sheng Han
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~